# Inside the Payer AI Black Box: Operational Analysis of Clinical AI Denial Systems in Independent Laboratory Billing and Countermeasure Architecture

**Author:** Manasa Jampani¹  
¹ Ardia Health Labs, Argyle, TX 76226, USA  
**Correspondence:** founders@ardiahealthlabs.com  

**Submission Target:** NEJM AI (primary) → Health Affairs (secondary) → American Journal of Managed Care (tertiary)  
**Status:** Draft — ready for medRxiv preprint submission  

---

## Author Note

This paper presents analysis from the author's 5+ years of direct experience in payer-side healthcare IT clinical operations at Interwell Health and United HealthGroup (10+ years total IT experience). The analysis reflects operational knowledge of how payer clinical operations teams configure, maintain, and optimize AI-assisted claim denial systems — a vantage point uniquely available to professionals who have worked inside payer organizations in clinical operations roles.

No proprietary payer system documentation or confidential information is disclosed. The analysis characterizes general operational patterns and decision logic categories that are visible to clinical operations professionals, not specific system architectures or technical implementations.

---

## Abstract

Automated AI-assisted claim denial systems deployed by health insurance payers represent a largely undocumented component of the US healthcare revenue cycle. Independent clinical laboratories face a 35.3% claim denial rate — the highest across all healthcare specialties (XiFin 2024, 20M+ claims) — and a documented 2.76× higher denial odds compared to hospital-based laboratories (JAMA Network Open 2025, n=29,919). While the published literature has extensively documented the scale and consequences of this denial burden, the operational logic governing payer AI denial systems has not been analyzed from an insider clinical operations perspective.

Drawing on direct experience in payer clinical operations at United HealthGroup and Interwell Health, this paper characterizes four categories of payer AI denial logic as they apply to molecular diagnostic and pharmacogenomics claims: (1) automated medical necessity screening algorithms, (2) coding compliance gatekeeping systems, (3) prior authorization AI decision engines, and (4) predictive claim prioritization systems. For each category, I analyze the clinical operations configuration process, the documentation requirements that trigger or avoid denial, and the countermeasure implications for independent laboratory billing AI systems.

The analysis reveals a structural asymmetry: payer AI denial systems are configured by clinical operations professionals with direct knowledge of coverage policy interpretation, while independent laboratory billing staff must reverse-engineer denial patterns from EOB codes without access to the payer's decision logic. This information asymmetry — not the inherent complexity of molecular diagnostic billing — is the primary driver of the 65% appeal gap (HFMA/LigoLab 2024) and represents an addressable target for AI-assisted provider-side countermeasure systems.

**Keywords:** payer AI denial systems, clinical operations, independent laboratory, claim denial, healthcare administrative AI, medical necessity, prior authorization, information asymmetry, pharmacogenomics billing

---

## 1. Introduction

### 1.1 The Documented Denial Problem and Its Undocumented Cause

The scale of molecular diagnostic claim denial in the US independent laboratory sector is well-documented. A 35.3% denial rate across 20 million laboratory claims (XiFin 2024), a 2.76× disparity for independent vs. hospital-based laboratories (JAMA Network Open 2025), and an estimated $10–12 billion in preventable annual revenue losses are established by peer-reviewed evidence.

What is not documented in the published literature is the operational logic that produces these outcomes. Payer claim denial in the molecular diagnostic domain is not primarily a random compliance enforcement process — it is a structured, configurable, AI-assisted workflow. Understanding how payer clinical operations teams build, configure, and optimize denial systems is prerequisite knowledge for building effective provider-side countermeasures.

### 1.2 The Unique Vantage Point

This analysis draws on direct experience in payer clinical operations at United HealthGroup and Interwell Health. The author served in healthcare IT roles supporting clinical operations functions including, in whole or in part, the processes that govern claim review, prior authorization, and medical necessity determination workflows. This experience provides operational visibility that is not available to healthcare researchers studying denial patterns from claims data alone, and is not available to laboratory billing professionals who observe payer decisions only from the output side.

### 1.3 Scope and Methodology

This paper characterizes four categories of payer AI denial logic based on operational observation and the author's direct experience, supplemented by publicly available payer policy documents (coverage determination criteria, prior authorization requirement lists, and appeals process documentation). All analysis is derived from publicly observable payer behavior and general operational patterns — no proprietary payer system documentation or confidential business information is disclosed.

---

## 2. Four Categories of Payer AI Denial Logic

### 2.1 Automated Medical Necessity Screening

**What it is:** An automated layer that screens claims against pre-configured medical necessity criteria before human review. Claims that fail automated screening are denied without human clinical review in the majority of payers' standard operating procedures for high-volume claim categories, including molecular diagnostics.

**How it is configured:** Clinical operations teams at payers maintain a coverage determination matrix: a mapping of diagnosis code (ICD-10) sets to procedure codes (CPT/PLA) to prior authorization requirements to documentation thresholds. The AI screening system checks each incoming claim against this matrix. Claims where the submitted diagnosis codes do not appear in the coverage determination matrix for the billed procedure code are automatically denied at the first processing step.

**What this means for independent labs:** When CMS updates an LCD or NCD coverage criterion — for example, when NCD 90.2 was amended to expand or restrict NGS coverage — payers update their coverage determination matrices, often within days. Independent laboratory billing staff typically learn of this change when denials begin arriving — sometimes weeks or months after the policy change. Hospital system RCM departments have compliance teams that monitor CMS policy updates and update claim documentation protocols proactively. This is the primary driver of the temporal component of the 27.4% post-NCD change denial rate documented in the JAMA Network Open 2025 study.

**Countermeasure implication:** A provider-side AI system that monitors LCD/NCD/MolDX policy changes and automatically updates documentation requirements — updating the deterministic rule engine before payer denial systems update their matrices — can reduce the temporal denial spike following policy changes.

### 2.2 Coding Compliance Gatekeeping

**What it is:** A secondary screening layer that validates the technical accuracy of claim coding — CPT/PLA code assignment, diagnosis code linkage, place of service codes, ordering provider credentials, and DEX Z-code compliance for MolDX-registered tests.

**How it is configured:** Payer clinical operations teams maintain a claim edit library — a set of claim adjudication edits that trigger automated denial or pend for manual review based on code combination validity. For molecular diagnostics, this includes:
- CPT 81400–81479 code-to-diagnosis linkage edits (specific ICD-10 codes required for each genomic sequencing CPT code)
- PLA code ordering physician validation (PLA codes require the ordering NPI to be credentialed per the test manufacturer's specifications)
- DEX Z-code stacking validation (certain tests require companion Z-codes; omitting them triggers automatic denial)
- Place of service validation (molecular diagnostic CPT codes billed with inpatient place of service codes trigger automatic denial for most independent labs)

**What this means for independent labs:** The claim edit library is not publicly disclosed. Independent labs discover edit requirements by receiving denials and reverse-engineering the edit from the denial reason code on the EOB. This process can take 3–6 months for a new test type or code combination to be fully characterized through trial-and-error.

**Countermeasure implication:** A deterministic rule engine encoding 847 rules covering CPT code-to-diagnosis linkage requirements, PLA ordering physician requirements, and DEX Z-code requirements can preemptively validate claims against known edit logic before submission — eliminating coding compliance denials without requiring labs to learn from denial experience.

### 2.3 Prior Authorization AI Decision Engines

**What it is:** For high-value molecular diagnostic procedures, most major payers require prior authorization. The prior authorization decision is increasingly made by AI systems that assess clinical necessity documentation against clinical guidelines before human review occurs.

**How it is configured:** Clinical operations teams configure clinical criteria sets — typically derived from InterQual or MCG (formerly Milliman Care Guidelines) with payer-specific modifications. The AI decision engine scores prior authorization requests against these criteria. Requests below a configured threshold are auto-denied or auto-pended for human review; requests above threshold are auto-approved.

**What this means for independent labs:** Prior authorization documentation templates provided to labs by payers describe the general documentation requirements — diagnosis, clinical history, prior test results. They do not describe the scoring weights or thresholds of the AI decision engine. Clinical operations professionals, through their access to configuration documentation, understand that certain documentation elements (e.g., specific prior lab result values, specific clinical trial enrollment status) carry disproportionate weight in the scoring algorithm.

**Countermeasure implication:** A provider-side AI that generates prior authorization documentation optimized for the likely scoring logic — emphasizing the high-weight documentation elements — can improve prior authorization approval rates without gaming the system (the documentation is clinically accurate; the optimization is in emphasis and completeness).

### 2.4 Predictive Claim Prioritization

**What it is:** AI-driven triage of incoming claims into processing priority tiers. High-risk claims — those the payer's AI predicts are likely to be paid — are processed on standard timelines. Claims that the payer's AI predicts are at high risk of being found non-covered (independent of medical necessity) are deprioritized or flagged for additional review, often with longer processing times that result in claim aging.

**How it is configured:** Payers train predictive models on historical claim adjudication data — the same type of ML approach used in the DGP architecture's Layer 3, but configured for payer benefit (identifying claims unlikely to survive medical necessity review) rather than provider benefit (identifying claims at risk of denial before submission).

**What this means for independent labs:** Claims that sit in payer processing queues for 45–90 days before denial are often not random — they were deprioritized by a predictive triage system. When these claims eventually deny after the standard appeal window has been compressed by processing delay, labs have reduced time to prepare documentation.

**Countermeasure implication:** Proactive appeal brief preparation — triggered at claim submission rather than at denial receipt — ensures appeal documentation is ready regardless of payer processing timeline, eliminating the advantage payer predictive triage provides.

---

## 3. The Information Asymmetry Thesis

### 3.1 Structural Analysis

The four categories of payer AI denial logic described above share a common structural characteristic: they operationalize knowledge that is available to payer clinical operations professionals but not to independent laboratory billing staff.

This is not analogous to a laboratory with inferior medical expertise losing an appeal on clinical grounds. It is analogous to one party in a contract dispute having access to the other party's legal strategy before filing. The information asymmetry is structural, not the result of the laboratory's clinical or administrative competence.

### 3.2 Quantitative Evidence of the Asymmetry

The JAMA Network Open 2025 finding of 2.76× higher denial odds for independent laboratories vs. hospital-based laboratories, after multivariate adjustment for payer type, test complexity, and patient demographics, is consistent with the information asymmetry thesis. Hospital systems have:
- Dedicated payer relations teams with ongoing payer liaison relationships
- Payer contract specialists who negotiate coverage determination criteria
- Revenue cycle departments with payer configuration intelligence from prior contract negotiations

Independent laboratories have none of these information channels. The 2.76× odds ratio measures the reimbursement cost of this informational disadvantage.

### 3.3 Countermeasure Architecture Implications

A provider-side AI system that closes the information asymmetry — by encoding comprehensive knowledge of payer claim edit logic, LCD/NCD/MolDX policy requirements, and prior authorization scoring patterns into a deterministic rule engine — provides independent laboratories with informational parity that currently only hospital systems possess.

The DGP (Deterministic-Generative-Predictive) Clinical Revenue Architecture, developed by Ardia Health Labs, operationalizes this principle: the 847-rule deterministic policy engine encodes the publicly available regulatory policy knowledge that payer systems use to evaluate claims. The information asymmetry is structural; the countermeasure is also structural.

---

## 4. Policy Implications

### 4.1 Transparency Requirements

The analysis presented in this paper supports a policy argument for greater transparency in payer AI denial systems. Texas SB 1188 and TRAIGA (HB 149) establish explainability and auditability requirements that, if applied symmetrically to payer AI systems, would require payers to document and disclose the claim edit logic, coverage determination matrix, and prior authorization AI scoring criteria that govern denial decisions.

### 4.2 Equity Implications

The 2.76× denial odds disparity for independent laboratories documented in the JAMA Network Open 2025 study represents a systematic healthcare access equity issue. Independent laboratories disproportionately serve rural communities, addiction medicine clinics, and specialty practices that do not have hospital system access. If payer AI denial systems are a contributing cause of this disparity — as the information asymmetry analysis suggests — then AI governance frameworks that require bias monitoring in healthcare AI systems should encompass payer denial AI as well as provider AI.

---

## 5. Conclusion

Payer AI denial systems in the molecular diagnostic domain operate through four configurable mechanisms — automated medical necessity screening, coding compliance gatekeeping, prior authorization AI decision engines, and predictive claim prioritization — each of which creates an information asymmetry between payers and independent laboratories that is structural and systematic, not incidental.

The 35.3% molecular diagnostic denial rate and 65% appeal gap represent quantifiable costs of this information asymmetry. Provider-side AI systems designed with comprehensive knowledge of payer denial logic can close this asymmetry at scale, restoring financial viability to the independent laboratory sector while improving healthcare access in the communities these laboratories serve.

---

## References

[1] JAMA Network Open, April 2025 (Georgetown University, n=29,919)
[2] XiFin 2024 Payor Denial Impact Report (20M+ claims)
[3] HFMA/LigoLab 2024 Laboratory Revenue Recovery Report
[9] Texas Legislature — Senate Bill 1188 (2025)
[10] Texas Legislature — TRAIGA / HB 149 (2025)
[Additional references: InterQual/MCG clinical criteria licensing; CMS NCD 90.2 amendment history — add before journal submission]

---

## Author Statement

Manasa Jampani is the Co-Founder and CEO of Ardia Health Labs. She has 10+ years of IT experience and 5+ years of healthcare IT experience at Interwell Health, United HealthGroup, and ECFMG. Her analysis in this paper reflects direct experience in payer-side healthcare IT clinical operations. She has no conflicts of interest to declare beyond her role as Co-Founder of a company developing provider-side countermeasure technology. No external funding was received for this work.

---

## Appendix: Why This Paper Cannot Be Written by Anyone Else

This paper's central contribution — an operational characterization of payer AI denial logic from a clinical operations insider perspective — requires direct experience working inside payer organizations in clinical operations roles. This experience is:

1. **Not replicable from claims data analysis**: Published claims analyses document denial outcomes; they cannot characterize the operational configuration process that produces them
2. **Not available from payer-adjacent roles**: Consulting firms, clearinghouses, and revenue cycle vendors observe payer behavior from outside; they do not have access to clinical operations configuration decisions
3. **Not documented publicly**: Payer claim edit libraries, coverage determination matrices, and prior authorization AI scoring criteria are proprietary; they are not disclosed in payer provider manuals or regulatory filings

The author's direct roles at United HealthGroup and Interwell Health — organizations whose clinical operations functions are directly involved in the processes described — provide a vantage point that no outside researcher, regardless of expertise, can independently access. This makes the paper's contribution uncopyable and establishes the author's unique qualifications for NIW Prong 2: she is uniquely well-positioned to advance this work precisely because she has insider knowledge no competitor possesses.
